Long‐term safety of biologics in the treatment of moderate‐to‐severe plaque psoriasis: review of current data

@article{Rustin2012LongtermSO,
  title={Long‐term safety of biologics in the treatment of moderate‐to‐severe plaque psoriasis: review of current data},
  author={M. Rustin},
  journal={British Journal of Dermatology},
  year={2012},
  volume={167}
}
  • M. Rustin
  • Published 2012
  • Medicine
  • British Journal of Dermatology
Conventional non‐biologic systemic agents are regarded as second‐line therapy for the treatment of moderate‐to‐severe plaque psoriasis after topical treatments. However, long‐term data have highlighted a number of safety concerns associated with their prolonged use. Biologic agents targeting specific immune mediators have emerged as an alternative treatment option for patients with moderate‐to‐severe plaque psoriasis who are unresponsive to, or intolerant of, non‐biologic systemic agents… Expand
98 Citations
Treating moderate to severe psoriasis – best use of biologics
Systemic Therapies for Psoriasis: An Evidence-Based Update
Biological therapies for psoriasis
An update on drug–drug interactions with biologics for the treatment of moderate-to-severe psoriasis
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
The long-term efficacy and safety of new biological therapies for psoriasis
  • K. Papp
  • Medicine
  • Archives of Dermatological Research
  • 2006
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Long-term etanercept in pediatric patients with plaque psoriasis.
...
1
2
3
4
5
...